Larimar Shares Fall, FDA Submission Seen as Next Hurdle
Larimar Therapeutics stock moved lower in late-morning trading Friday as investors watched for a June regulatory update on its top Friedreich’s ataxia treatment. LRMR was down 3.36% to $3.45 at 11:02 a.m. EDT while the market was still open, according to StockAnalysis data. Larimar is aiming to kick off a rolling Biologics License Application for nomlabofusp in June. A BLA is the FDA’s main filing for companies looking to bring a biologic drug to the U.S. market. Accelerated approval means the application could get cleared using a surrogate marker rather than waiting for full results.